Clear Scientific Presents at 87th Annual Scientific Meeting of the College on Problems of Drug Dependence
- Clear Scientific
- Jul 16
- 1 min read
New Orleans, Louisiana | June 2025
On June 16, 2025, Piercen Oliver PhD, VP of R&D and Xinhua Li PhD, Executive Vice President Drug Development of Clear Scientific Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, presented a poster titled Development of CS-1103 a First-in-Class Treatment for Methamphetamine Intoxication at the 87th
in New Orleans, LA.
The presentation described the chemistry, anticipated benefits, Phase 1 results and development status of CS-1103, Clear’s first-in-class sequestrant-based therapeutic for rapid treatment of methamphetamine intoxication. CS-1103 immediately binds and inactivates threat agents, rapidly reversing their toxic effects and accelerating their clearance from the body.
About Clear Scientific
Clear Scientific, co-founded by Prof. George Whitesides of Harvard University, is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. This approach focuses on development of highly selective, small molecule sequestrants that bind, immediately inactivates intoxicants, and rapidly clear excess compounds from the body.
For more information, visit https://www.clearsci.com.
Comments